Analytical Data
-
Gene name
CCL11
- Application
-
Alternative Names
CCL11；SCYA11；；Eotaxin
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P51671
-
Expression Region
24-97aa
-
AA Sequence
GPASVPTTCC FNLANRKIPL QRLESYRRIT SGKCPQKAVI FKTKLAKDICADPKKKWVQD SMKYLDQKSP TPKP
-
Molecular Weight
8.4 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CCL11, also known as Eotaxin-1, is a chemokine primarily involved in the recruitment of eosinophils and basophils to sites of inflammation, playing a significant role in allergic responses and asthma. Its involvement in these conditions has made it a critical focus of research aimed at understanding the underlying mechanisms of allergic diseases and potential therapeutic interventions. Recombinant CCL11 proteins have been developed for various applications, including in vitro studies and therapeutic strategies targeting allergic inflammation. The ability to produce CCL11 in a recombinant form allows researchers to elucidate its structural and functional characteristics, assess its role in immune responses, and investigate its potential as a biomarker for allergic diseases. Additionally, studies on CCL11 have revealed its involvement in various pathophysiological processes beyond allergies, including its effects on neuronal cells and its association with autoimmune diseases. As such, the exploration of recombinant CCL11 is vital not only for advancing the basic understanding of chemokine biology but also for developing novel therapeutic approaches to manage inflammatory and allergic conditions.
